English

Navamedic: Q2 2006 presentation at Felix 23 August at 08:00

Report this content
(Lysaker, Norway, 15 August, 2006) Navamedic ASA invites to a presentation of the company's Q2 2006 results on 23 August 2006. The presentation will take place at Felix Conference Centre at Aker Brygge, Bryggetorget 3, 0114 Oslo, and will start at 08:00. Participants are requested to register at firma@navamedic.com or by calling +47 67 11 25 40.
For further information, please contact:


CEO Øyvind W. Brekke, Navamedic
E-mail: oyvind.brekke@navamedic.com
Office: +47 67 11 25 40, Mobile: +47 91 19 81 64


CFO Jon W. Ringvold, Navamedic
E-mail: jon.ringvold@navamedic.com
Office: +47 67 11 25 44 Mobile: +47 99 15 85 34


About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world's population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company's products will be sold through a network of sales, marketing and distribution partners. Navamedic's product Glucomed has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.

Subscribe